What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Heart failure (n=331). Intervention: Diabetes mellitus vs. Without diabetes mellitus. Primary outcome: Polypharmacy (use of eight or more medications) (AOR 6.55, 95% CI 3.71-11.56).

November 13, 2023Saudi Pharmaceutical JournalOpen Access

Prevalence of polypharmacy in heart failure patients: A retrospective cross-sectional study in a tertiary hospital in Saudi Arabia

View Full Paper

Ask AI

Bookmark

Key result

Comorbid diabetes in HF is linked to ~6.6-fold higher odds of polypharmacy.

AOR 6.55
95% CI 3.71-11.56
n=331

Why the study?

This study aimed to evaluate the prevalence and predictors of polypharmacy in patients with heart failure.

Population

331 adult outpatients with heart failure in Saudi Arabia

Design

Retrospective cross-sectional study

Authors

MAMohammed M. AlsultanKing Fahd Medical City RARabab AlamerImam Abdulrahman Bin Faisal University FAFatimah AlammarImam Abdulrahman Bin Faisal University

Discussion

Member takes

Implication

May warrant polypharmacy review in HF patients with diabetes; hypothesis-generating observational data requiring prospective confirmation.

Study Design

Type

Cross-Sectional (n=331)

Multicenter

Structured PICO

Population

331 adult outpatients with heart failure, excluding those with cancer, evaluated for the prevalence and predictors of polypharmacy.

Outcome

Prevalence of polypharmacy (defined as the use of eight or more medications)

Main Result

Odds Ratio: 6.55 (95% CI 3.71–11.56)

Polypharmacy is highly prevalent (39.88%) among heart failure outpatients, with comorbid diabetes mellitus being a strong predictor of using eight or more medications.

Cite This Study

Alsultan et al. (2023) conducted a cross-sectional in Heart failure (n=331). Diabetes mellitus vs. Without diabetes mellitus was evaluated on Polypharmacy (use of eight or more medications) (AOR 6.55, 95% CI 3.71-11.56). Among patients with heart failure, comorbid diabetes mellitus was associated with a significantly higher odds of polypharmacy (AOR 6.55; 95% CI 3.71-11.56).

synapsesocial.com/papers/6a484db0a567c8cbc92f7d91 https://doi.org/10.1016/j.jsps.2023.101875

View Full Paper

Ask AI

Bookmark

November 13, 2023Saudi Pharmaceutical JournalOpen Access

Prevalence of polypharmacy in heart failure patients: A retrospective cross-sectional study in a tertiary hospital in Saudi Arabia

View Full Paper

Ask AI

Bookmark

Key result

Comorbid diabetes in HF is linked to ~6.6-fold higher odds of polypharmacy.

AOR 6.55
95% CI 3.71-11.56
n=331

Why the study?

This study aimed to evaluate the prevalence and predictors of polypharmacy in patients with heart failure.

Population

331 adult outpatients with heart failure in Saudi Arabia

Design

Retrospective cross-sectional study

Authors

MAMohammed M. AlsultanKing Fahd Medical City RARabab AlamerImam Abdulrahman Bin Faisal University FAFatimah AlammarImam Abdulrahman Bin Faisal University

Discussion

Member takes

Implication

May warrant polypharmacy review in HF patients with diabetes; hypothesis-generating observational data requiring prospective confirmation.

Study Design

Type

Cross-Sectional (n=331)

Multicenter

Structured PICO

Population

331 adult outpatients with heart failure, excluding those with cancer, evaluated for the prevalence and predictors of polypharmacy.

Outcome

Prevalence of polypharmacy (defined as the use of eight or more medications)

Main Result

Odds Ratio: 6.55 (95% CI 3.71–11.56)

Polypharmacy is highly prevalent (39.88%) among heart failure outpatients, with comorbid diabetes mellitus being a strong predictor of using eight or more medications.

Cite This Study

synapsesocial.com/papers/6a484db0a567c8cbc92f7d91 https://doi.org/10.1016/j.jsps.2023.101875

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark